PetVivo Holdings Announces Digital Landia’s Publication of Technical Whitepaper Validating AgenticPet AI Framework Under Exclusive 10-Year Licensing Agreement
PetVivo (OTCQX: PETV) announced publication of Digital Landia’s technical whitepaper validating the AgenticPet AI Framework that underpins PetVivo’s exclusive 10-year white-label licensing agreement signed October 2025.
The whitepaper describes a production-ready, multi-agent veterinary AI architecture with claimed 90–98% client acquisition cost reduction, five patent-pending innovations, enterprise features (end-to-end encryption, blockchain audit trails, HIPAA-aligned privacy), and 99.9% uptime design. PetVivo targets a Q1 2026 dual launch with B2C and B2B platforms and pre-launch registration opening January 2026.
PetVivo (OTCQX: PETV) ha annunciato la pubblicazione del whitepaper tecnico di Digital Landia che convalida il AgenticPet AI Framework su cui si basa l'esclusivo accordo di licenza in white-label di 10 anni firmato da PetVivo nell'ottobre 2025.
Il whitepaper descrive un'architettura AI veterinaria multi-agente pronta per la produzione con una presunta riduzione dei costi di acquisizione dei clienti del 90–98%, cinque innovazioni in attesa di brevetto, caratteristiche aziendali (crittografia end-to-end, tracciabilità tramite blockchain, privacy allineata a HIPAA) e una progettazione con uptime al 99,9%. PetVivo punta a un lancio duale nel primo trimestre 2026 con piattaforme B2C e B2B e l'apertura della registrazione pre-lancio a gennaio 2026.
PetVivo (OTCQX: PETV) anunció la publicación del whitepaper técnico de Digital Landia que valida el AgenticPet AI Framework que sustenta el exclusivo acuerdo de licencia de marca blanca de 10 años firmado por PetVivo en octubre de 2025.
El whitepaper describe una arquitectura de IA veterinaria multi-agente, lista para producción, con una supuesta reducción del 90–98% en los costos de adquisición de clientes, cinco innovaciones en espera de patente, características empresariales (cifrado de extremo a extremo, trazas de auditoría en blockchain, privacidad alineada con HIPAA) y un diseño de disponibilidad del 99,9%. PetVivo apunta a un doble lanzamiento en el primer trimestre de 2026 con plataformas B2C y B2B y la apertura de registro previo al lanzamiento en enero de 2026.
PetVivo (OTCQX: PETV) 는 Digital Landia의 기술 백서 공개를 발표했으며, AgenticPet AI Framework가 PetVivo의 10년 비독점 화이트 라벨 라이선스 계약의 기초임을 확인합니다(2025년 10월 체결).
백서에는 생산 준비가 된 다중 에이전트 수의학 AI 아키텍처가 설명되며, 클라이언트 확보 비용의 90–98% 절감, 특허 출원 중인 다섯 가지 혁신, 엔터프라이즈 기능(종단 간 암호화, 블록체인 감사 로그, HIPAA에 부합하는 개인정보 보호), 및 99.9% 가동 시간 설계가 포함됩니다. PetVivo는 2026년 1분기에 B2C 및 B2B 플랫폼으로의 이중 출시를 목표로 하며, 예비 출시 등록은 2026년 1월에 오픈합니다.
PetVivo (OTCQX: PETV) a annoncé la publication du whitepaper technique de Digital Landia validant le AgenticPet AI Framework sur lequel repose l'accord exclusif de licence en marque blanche de 10 ans signé par PetVivo en octobre 2025.
Le whitepaper décrit une architecture d'IA vétérinaire multi-agent prête pour la production avec une réduction présumée des coûts d'acquisition client de 90–98%, cinqu innovations en attente de brevet, des fonctionnalités d'entreprise (cryptage de bout en bout, traces d'audit blockchain, confidentialité conforme HIPAA) et une conception avec une disponibilité de 99,9%. PetVivo vise un double lancement au premier trimestre 2026 avec des plateformes B2C et B2B et l'ouverture des pré-inscriptions en janvier 2026.
PetVivo (OTCQX: PETV) kündigte die Veröffentlichung des technischen Whitepapers von Digital Landia an, das das AgenticPet AI Framework validiert, auf dem PetVivos exklusives 10-Jahres-White-Label-Lizenzabkommen basiert, das im Oktober 2025 unterzeichnet wurde.
Das Whitepaper beschreibt eine produktionsreife, multi-Agenten-Veterinär-KI-Architektur mit behaupteter Kostensenkung bei der Kundengewinnung von 90–98%, fünf patentierte Innovationen, Unternehmensmerkmale (End-to-End-Verschlüsselung, Blockchain-Audit-Trails, HIPAA-ausgerichtete Privatsphäre) und einem 99,9%igen Ausfallssicherheits-Design. PetVivo plant eine Doppelmarkteinführung im 1. Quartal 2026 mit B2C- und B2B-Plattformen und die Vorregistrierung öffnet im Januar 2026.
PetVivo (OTCQX: PETV) أعلنت عن نشر الورقة البيضاء التقنية الخاصة بـ Digital Landia التي تتحقق من إطار AgenticPet AI الذي يدعم اتفاقية الترخيص البيضاء الحصرية لمدة 10 سنوات الموقعة من PetVivo في أكتوبر 2025.
توصف الورقة البيضاء بنية ذكاء اصطناعي بيطري متعددة العوامل جاهزة للإنتاج مع ادعاء خفض تكاليف اكتساب العملاء بنسبة 90–98%، خمس ابتكارات قيد البراءة، وميزات مؤسسية (التشفير من الطرف إلى الطرف، سجلات تدقيق على blockchain، خصوصية متوافقة مع HIPAA)، وتصميم يوفر وقت تشغيل بنسبة 99.9%.
- Exclusive 10-year white-label licensing agreement (October 2025)
- 90–98% reduction in client acquisition costs claimed
- Five patent-pending innovations protecting core framework
- Enterprise architecture with 99.9% uptime design and encryption
- Established distribution: partnership with VGP (7,300 members) and > 1,000 clinics
- Targeted commercial launch in Q1 2026 with pre-launch in January 2026
- None.
Insights
Whitepaper and exclusive 10-year license materially de‑risk technical readiness and enable near-term commercial rollout in Q1 2026.
Digital Landia’s published whitepaper documents a multi-agent AI architecture claimed to be production-ready and supports PetVivo’s October exclusive
Key dependencies and risks include independent verification of the whitepaper’s technical claims, successful integration with practice-management systems, and clinic adoption across the stated network (over 1,000 clinics and partnership access to 7,300 VGP members). The stated reductions in client acquisition cost (
Concrete items to watch: deployment milestones and uptime metrics during the
Comprehensive Documentation Confirms Production-Ready Architecture for PetVivo’s Veterinary Platform Launching Q1 2026
MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., an emerging biomedical device company focused on commercializing groundbreaking medical products and therapeutics for horses and companion animals, today announced that its exclusive AI technology partner, Digital Landia Holding Corp., has published a comprehensive technical whitepaper documenting the AgenticPet AI Framework powering PetVivo's B2B veterinary-practice platform.
The whitepaper validates the technical foundation underlying PetVivo's October 2025 exclusive 10-year white-label licensing agreement, providing veterinary professionals, investors, and industry stakeholders with detailed visibility into the multi-agent artificial intelligence architecture that enables transformative clinical and economic benefits for veterinary practices.
TECHNICAL DUE DILIGENCE VALIDATED
"Our October announcement represented months of rigorous technical due diligence," stated John Lai, Chief Executive Officer of PetVivo Holdings, Inc. "We don't partner lightly—especially on decade-long agreements. Today's whitepaper demonstrates exactly what we evaluated: a production-ready AI framework with genuine clinical utility, protected intellectual property, and enterprise-grade architecture capable of serving our entire veterinary network. This isn't a proof of concept; it's fully deployable infrastructure."
FRAMEWORK CAPABILITIES ALIGNED WITH VETERINARY NEEDS
The published whitepaper details technical capabilities that directly address modern veterinary practice challenges, including a 90 to 98 percent reduction in client acquisition costs through seamless pet-parent data flows; universal diagnostic assistance with nine specialized AI agents available across entire clinic patient bases; and enhanced Gen Z market access through a mobile-first consumer experience aligned with digital-native expectations.
INTELLECTUAL PROPERTY PROTECTION
The whitepaper reveals five patent-pending innovations protecting the AgenticPet framework’s core functionality, providing PetVivo with significant competitive advantages under its exclusive 10-year licensing agreement: (1) distributed agent-certification systems; (2) swarm-intelligence coordination protocols; (3) privacy-preserving health-data synthesis; (4) real-time veterinary-integration layers; and (5) adaptive learning pipelines.
ENTERPRISE-READY ARCHITECTURE
The technical documentation demonstrates an architecture specifically designed for professional veterinary-practice requirements, including end-to-end encryption, blockchain audit trails, HIPAA-aligned privacy frameworks, API specifications for practice-management-system integration, automated health-history uploads, and cloud-native infrastructure ensuring over 99.9 percent uptime reliability.
"The whitepaper makes clear that Digital Landia built this framework for veterinarians—not just pet parents," noted Mr. Lai. "The enterprise-grade security, seamless integration specifications, and clinical workflow design demonstrate a deep understanding of veterinary practice operations."
DISTRIBUTION NETWORK READY
PetVivo's established product distribution network, including its partnership with Veterinary Growth Partners (VGP), a prominent veterinary association that has more than 7,300 veterinary professional members, and its established relationships with over 1,000 clinics already using its existing SPRYNG® and PrecisePRP™ product lines, positions the Company to rapidly deploy the AgenticPet platform across a rapidly expanding veterinary industry.
STRATEGIC RATIONALE FOR EXCLUSIVE AGREEMENT
PetVivo's exclusive 10-year licensing structure reflects its confidence in the framework’s competitive positioning and multiple revenue streams, including B2B subscriptions, lead-generation fees, and premium features. Platform network effects increase value as adoption grows, supported by strong demographic tailwinds as Gen Z pet ownership rises approximately 43.5 percent annually.
PARTNERSHIP MILESTONE PROGRESSION
Today's publication marks the third major milestone in the PetVivo–Digital Landia partnership: (1) the March 2025 strategic alliance announcement; (2) the October 2025 exclusive 10-year licensing agreement; and (3) the November 2025 comprehensive technical whitepaper enabling independent evaluation of the framework.
Q1 2026 DUAL-PLATFORM LAUNCH
The documented technical foundation supports a Q1 2026 commercial launch featuring Digital Landia's B2C AgenticPet app and PetVivo's B2B veterinary platform with white-labeled AI diagnostic assistance. Pre-launch registration opens in January 2026.
WHITEPAPER ACCESS
The AgenticPet AI Framework Technical Whitepaper is publicly available at: https://digital-landia.gitbook.io/agentic-pet-whitepaper/.
PetVivo encourages veterinary professionals, investors, and industry stakeholders to review this comprehensive technical documentation.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP®, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What did PetVivo (PETV) announce on November 17, 2025 about AgenticPet AI?
How does the AgenticPet whitepaper claim to reduce costs for veterinary practices for PETV?
When will PetVivo (PETV) launch the AgenticPet platform commercially?
What IP and security features does the AgenticPet whitepaper highlight for PETV?
How extensive is PetVivo’s distribution reach ahead of the PETV platform launch?
